[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01GA01, streptomycin, Leuprolide may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Leuprolide may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Leuprolide may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Leuprolide.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Leuprolide.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Leuprolide.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sulpiride.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Leuprolide.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Leuprolide.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Tacrine.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Leuprolide.]
[N05CD07, temazepam, Leuprolide may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Leuprolide.]
[B01AE07, dabigatran etexilate, Leuprolide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Leuprolide may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Tetracaine.]
[S03AA02, tetracycline, Leuprolide may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Leuprolide.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Leuprolide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Leuprolide may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Leuprolide.]
[R06AD03, thiethylperazine, Leuprolide may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Leuprolide.]
[G04BE06, moxisylyte, Leuprolide may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Leuprolide may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Leuprolide may decrease the excretion rate of Ticlopidine which could result in a higher serum level.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Leuprolide.]
[P01AB02, tinidazole, Leuprolide may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Leuprolide may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Leuprolide.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Leuprolide.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N02AX02, tramadol, Leuprolide may decrease the excretion rate of Tramadol which could result in a higher serum level.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Leuprolide.]
[S01BA05, triamcinolone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Triazolam.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Leuprolide may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Leuprolide may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Leuprolide.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Leuprolide.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Leuprolide.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Leuprolide.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Leuprolide.]
[R03DX07, roflumilast, Leuprolide may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Leuprolide may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Vandetanib.]
[R02AA14, oxyquinoline, Leuprolide may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Leuprolide.]
[S01AA28, vancomycin, Leuprolide may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Leuprolide.]
[B01AF01, rivaroxaban, Leuprolide may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Leuprolide.]
[C08DA01, verapamil, Leuprolide may decrease the excretion rate of Verapamil which could result in a higher serum level.]
[N06AX09, viloxazine, Leuprolide may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Vincristine.]
[B03BA01, vitamin B12, Leuprolide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.]
[B01AA03, warfarin, Leuprolide may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Zuclopenthixol.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Vemurafenib.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pamidronic acid.]
[M05BA05, tiludronic acid, Leuprolide may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Leuprolide may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Crizotinib.]
[A02BC04, rabeprazole, Leuprolide may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Leuprolide may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Leuprolide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Leuprolide.]
[J01DH04, doripenem, Leuprolide may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Leuprolide.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Atropine.]
[M01CB03, auranofin, Leuprolide may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Leuprolide.]
[L01BC07, azacitidine, Leuprolide may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Leuprolide may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Leuprolide may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Leuprolide may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Baclofen.]
[A08AA11, lorcaserin, Leuprolide may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Leuprolide.]
[L02BB04, enzalutamide, Leuprolide may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[D02BA02, octinoxate, Leuprolide may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Leuprolide.]
[N04BD02, rasagiline, Leuprolide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lercanidipine.]
[V09IX04, fluorodeoxyglucose F18, Leuprolide may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Leuprolide.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Sildenafil.]
[V08CA11, gadofosveset, Leuprolide may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Leuprolide may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Leuprolide.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide.]
[A16AX09, glycerol phenylbutyrate, Leuprolide may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Leuprolide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Moxifloxacin.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Leuprolide.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Leuprolide.]
[L03AA12, ancestim, Leuprolide may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Leuprolide.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Leuprolide.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[L01EE01, trametinib, Leuprolide may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Leuprolide may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Leuprolide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Bepridil.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Leuprolide.]
[C02KX04, macitentan, Leuprolide may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, Leuprolide may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Leuprolide may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[J05AP08, sofosbuvir, Leuprolide may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Leuprolide.]
[C01CA27, droxidopa, Leuprolide may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, Leuprolide may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Leuprolide may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Leuprolide may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Betamethasone.]
[V03AB34, fomepizole, Leuprolide may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Bezafibrate.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Leuprolide.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Leuprolide.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Leuprolide.]
[V08AA01, diatrizoic acid, Leuprolide may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Leuprolide may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Leuprolide.]
[S03AA06, gentamicin, Leuprolide may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AF03, edoxaban, Leuprolide may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Leuprolide.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Panobinostat.]
[N02BE01, acetaminophen, Leuprolide may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Leuprolide may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Leuprolide.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Leuprolide.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Leuprolide.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Acipimox.]
[V03AB37, idarucizumab, Leuprolide may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Trabectedin.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Leuprolide.]
[L01XG03, ixazomib, Leuprolide may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Leuprolide.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Leuprolide.]
[M04AB05, lesinurad, Leuprolide may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N03AX23, brivaracetam, Leuprolide may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Leuprolide may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Leuprolide.]
[A02AD05, aluminum magnesium silicate, Leuprolide may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Leuprolide.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Levobupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Leuprolide.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Leuprolide.]
[N05BE01, buspirone, Leuprolide may decrease the excretion rate of Buspirone which could result in a higher serum level.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Artemether.]
[M02AA03, clofezone, Leuprolide may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Leuprolide.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[A06AH05, naldemedine, Leuprolide may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Leuprolide.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Leuprolide.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Leuprolide may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J05AF06, abacavir, Leuprolide may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[N07XX13, valbenazine, Leuprolide may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Infliximab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Leuprolide.]
[L01BC06, capecitabine, Leuprolide may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Leuprolide.]
[C07AB07, bisoprolol, Leuprolide may decrease the excretion rate of Bisoprolol which could result in a higher serum level.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Leuprolide may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Leuprolide.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Leuprolide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Leuprolide.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Leuprolide.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Macimorelin.]
[L02BB05, apalutamide, Leuprolide may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Leuprolide may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Carbimazole.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Carbinoxamine.]
[L04AA37, baricitinib, Leuprolide may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Encorafenib.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01GB14, plazomicin, Leuprolide may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Leuprolide.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ivosidenib.]
[A16AX14, migalastat, Leuprolide may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Leuprolide may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Leuprolide.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Leuprolide.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Leuprolide may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Leuprolide.]
[L01AD01, carmustine, Leuprolide may decrease the excretion rate of Carmustine which could result in a higher serum level.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amifampridine.]
[A06AX05, prucalopride, Leuprolide may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Leuprolide.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Leuprolide.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ciprofibrate.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Leuprolide.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clarithromycin.]
[N06BA14, solriamfetol, Leuprolide may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N05BA09, clobazam, Leuprolide may decrease the excretion rate of Clobazam which could result in a higher serum level.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ubidecarenone.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Entrectinib.]
[N07XX11, pitolisant, Leuprolide may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Leuprolide.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Leuprolide.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Daptomycin.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[M09AX08, golodirsen, Leuprolide may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Leuprolide.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Leuprolide may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Leuprolide.]
[R02AA03, dichlorobenzyl alcohol, Leuprolide may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Leuprolide may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C08CA16, clevidipine, Leuprolide may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Leuprolide.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[V08CA05, mangafodipir, Leuprolide may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Dyclonine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Leuprolide.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Leuprolide.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chloroquine.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Leuprolide.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Leuprolide may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N02BA03, choline salicylate, Leuprolide may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Etofibrate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Leuprolide.]
[M01AX25, chondroitin sulfates, Leuprolide may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Leuprolide.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C01CA19, fenoldopam, Leuprolide may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[J01DD15, cefdinir, Leuprolide may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Leuprolide.]
[N02BG07, flupirtine, Leuprolide may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Leuprolide.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Leuprolide.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Leuprolide.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cimetidine.]
[V08CA04, gadoteridol, Leuprolide may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ciprofloxacin.]
[L01XA01, cisplatin, Leuprolide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Leuprolide is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Leuprolide may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Leuprolide may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Leuprolide may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clemastine.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Leuprolide.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Leuprolide.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Clofibrate.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Leuprolide.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clomipramine.]
[N03AE01, clonazepam, Leuprolide may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[J05AH02, oseltamivir, Leuprolide may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Leuprolide.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Leuprolide.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Leuprolide.]
[J01GB12, arbekacin, Leuprolide may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Cocaine.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Colchicine.]
[J01XB01, colistin, Leuprolide may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Leuprolide.]
[A04AA03, tropisetron, Leuprolide may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Leuprolide.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Leuprolide.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Leuprolide.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Telithromycin.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Desloratadine.]
[J05AB14, valganciclovir, Leuprolide may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Leuprolide may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Leuprolide may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Leuprolide may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Leuprolide may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Leuprolide may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N02CC05, almotriptan, Leuprolide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Leuprolide.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Emedastine.]
[N05BA10, ketazolam, Leuprolide may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Leuprolide.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Leuprolide.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Leuprolide.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Leuprolide.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Leuprolide.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Nafarelin.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lomefloxacin.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C09AA03, lisinopril, Leuprolide may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Leuprolide may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mebeverine.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Leuprolide.]
[J01DH02, meropenem, Leuprolide may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Adenosine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Leuprolide.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Leuprolide.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[S01XA18, cyclosporine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cyclosporine.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Leuprolide.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Leuprolide.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Rosuvastatin.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cytarabine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Leuprolide.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[L01AX04, dacarbazine, Leuprolide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N07BB05, nalmefene, Leuprolide may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[S01GX04, nedocromil, Leuprolide may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, Leuprolide may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Leuprolide may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Leuprolide may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[B01AX05, fondaparinux, Leuprolide may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Leuprolide.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Leuprolide.]
[H01BA02, desmopressin, Leuprolide may decrease the excretion rate of Desmopressin which could result in a higher serum level.]
[V04CH02, indigo carmine, Leuprolide may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Leuprolide may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxaliplatin.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[S03BA01, dexamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Dexamethasone.]
[N06BA02, dextroamphetamine, Leuprolide may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[P03AC04, permethrin, Leuprolide may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Leuprolide may decrease the excretion rate of Diazepam which could result in a higher serum level.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Cinchocaine.]
[R05DA08, pholcodine, Leuprolide may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Leuprolide.]
[A03AA07, dicyclomine, Leuprolide may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Leuprolide may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Leuprolide.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Leuprolide.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Erlotinib.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Leuprolide.]
[D07XC04, diflucortolone, Leuprolide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Leuprolide.]
[C01AA05, digoxin, Leuprolide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AA03, hydromorphone, Leuprolide may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, Leuprolide may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Leuprolide.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Leuprolide.]
[H03BC01, potassium perchlorate, Leuprolide may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Leuprolide may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Leuprolide may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Leuprolide may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Diphenhydramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cisapride.]
[S01AX06, resorcinol, Leuprolide may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Leuprolide.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Leuprolide.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Leuprolide.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Leuprolide.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Leuprolide.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Leuprolide.]
[G04BE08, tadalafil, Leuprolide may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Leuprolide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, Leuprolide may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Domperidone.]
[C01CA04, dopamine, Leuprolide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Leuprolide.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Leuprolide.]
[J01AA02, doxycycline, Leuprolide may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Leuprolide.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Leuprolide.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Droperidol.]
[A08AA10, sibutramine, Leuprolide may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Simvastatin.]
[A12CA02, sodium sulfate, Leuprolide may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Leuprolide may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sultopride.]
[N02CC01, sumatriptan, Leuprolide may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Leuprolide may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Leuprolide.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Temafloxacin.]
[L01AX03, temozolomide, Leuprolide may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Terodiline.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Enalapril.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N06AG03, toloxatone, Leuprolide may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Leuprolide.]
[N03AX11, topiramate, Leuprolide may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Leuprolide may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Leuprolide.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Leuprolide.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Leuprolide.]
[N06AX16, venlafaxine, Leuprolide may decrease the excretion rate of Venlafaxine which could result in a higher serum level.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N03AX15, zonisamide, Zonisamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Leuprolide.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C02AC02, guanfacine, Leuprolide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Leuprolide.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Valproic acid.]
[L03AX05, pidotimod, Leuprolide may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Erythromycin.]
[N05CD04, estazolam, Leuprolide may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Leuprolide may decrease the excretion rate of Pantoprazole which could result in a higher serum level.]
[G03CA03, estradiol, Leuprolide may decrease the excretion rate of Estradiol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Leuprolide may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, Leuprolide may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fluvastatin.]
[V08CA03, gadodiamide, Leuprolide may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Leuprolide.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Etidocaine.]
[N01AX07, etomidate, Leuprolide may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Leuprolide.]
[L04AD02, tacrolimus, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Tacrolimus.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Leuprolide.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Terfenadine.]
[P01AX07, trimetrexate, Leuprolide may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Leuprolide may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, Leuprolide may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Leuprolide.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Leuprolide.]
[S02BA08, fluocinolone acetonide, Leuprolide may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Leuprolide may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, Leuprolide may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Leuprolide may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Leuprolide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Leuprolide.]
[A16AA01, levocarnitine, Leuprolide may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Leuprolide.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fendiline.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N02AB03, fentanyl, Leuprolide may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Leuprolide.]
[L01BB06, clofarabine, Leuprolide may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cladribine.]
[N07AX03, cevimeline, Leuprolide may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Leuprolide may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Flecainide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Leuprolide.]
[J02AX01, flucytosine, Leuprolide may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Leuprolide may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ethanol.]
[L01BC09, floxuridine, Leuprolide may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Leuprolide.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Flupentixol.]
[N05CD01, flurazepam, Leuprolide may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluspirilene.]
[L02BB01, flutamide, Leuprolide may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Leuprolide may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Leuprolide may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[L01BC03, tegafur, Leuprolide may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Leuprolide may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Leuprolide.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Leuprolide.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Leuprolide.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Leuprolide.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Leuprolide.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Leuprolide.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Leuprolide.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Leuprolide.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Leuprolide.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Leuprolide.]
[N05CM18, dexmedetomidine, Leuprolide may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dofetilide.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Leuprolide.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Leuprolide.]
[M01CB04, aurothioglucose, Leuprolide may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Leuprolide may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Leuprolide may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Leuprolide may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Leuprolide.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quetiapine.]
[N06BX13, idebenone, Leuprolide may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Leuprolide.]
[M04AA01, allopurinol, Leuprolide may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Leuprolide.]
[G03DC01, allylestrenol, Leuprolide may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C01CE02, milrinone, Leuprolide may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxatomide.]
[C09AA04, perindopril, Leuprolide may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Leuprolide may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Leuprolide may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Leuprolide may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, Leuprolide may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Leuprolide.]
[B05AA07, hetastarch, Leuprolide may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Hydroxyzine.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Risedronic acid.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[B05XA08, sodium acetate, Leuprolide may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Leuprolide may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Terlipressin.]
[R01AD07, tixocortol, Leuprolide may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Leuprolide.]
[L01CE01, topotecan, Leuprolide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[A11HA07, inositol, Leuprolide may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Leuprolide may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Leuprolide may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Leuprolide.]
[N05BA12, alprazolam, Leuprolide may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Leuprolide may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Leuprolide.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Anagrelide.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Stavudine.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Leuprolide.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Isoniazid.]
[J05AX05, inosine pranobex, Leuprolide may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Leuprolide.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Isotretinoin.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ivermectin.]
[S01AA24, kanamycin, Leuprolide may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Somatotropin.]
[N01AX03, ketamine, Leuprolide may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[B01AC22, prasugrel, Leuprolide may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Leuprolide.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Leuprolide.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nalidixic acid.]
[C07AG01, labetalol, Leuprolide may decrease the excretion rate of Labetalol which could result in a higher serum level.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Leuprolide.]
[A06AX03, lubiprostone, Leuprolide may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Leuprolide.]
[S01AA21, amikacin, Leuprolide may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Loperamide.]
[N05BA06, lorazepam, Leuprolide may decrease the excretion rate of Lorazepam which could result in a higher serum level.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lovastatin.]
[B05XA11, magnesium chloride, Leuprolide may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Leuprolide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[L01BA05, pralatrexate, Leuprolide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Leuprolide.]
[C02BB01, mecamylamine, Leuprolide may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mefloquine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DX01, memantine, Leuprolide may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Leuprolide may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Mepivacaine.]
[G04BX16, tiopronin, Leuprolide may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Paliperidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Methadone.]
[N06BA03, methamphetamine, Leuprolide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lamivudine.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, Leuprolide may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Leuprolide may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Leuprolide may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[L04AX03, methotrexate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Methotrexate.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Leuprolide.]
[D05BA02, methoxsalen, Leuprolide may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Methyldopa.]
[V04CG05, methylene blue, Leuprolide may decrease the excretion rate of Methylene blue which could result in a higher serum level.]
[G03EK01, methyltestosterone, Leuprolide may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Metoclopramide.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Leuprolide may decrease the excretion rate of Metoprolol which could result in a higher serum level.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Leuprolide.]
[V04CD01, metyrapone, Leuprolide may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N05CD08, midazolam, Leuprolide may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mifepristone.]
[J05AH01, zanamivir, Leuprolide may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Minocycline.]
[L03AC01, aldesleukin, Leuprolide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amitriptyline.]
[A04AA05, palonosetron, Leuprolide may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Leuprolide may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Leuprolide may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Pazopanib.]
[L04AA06, mycophenolic acid, Leuprolide may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Raltegravir.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Leuprolide.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Leuprolide.]
[C07AA12, nadolol, Leuprolide may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, Leuprolide may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Leuprolide may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Naltrexone.]
[N06BA01, amphetamine, Leuprolide may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Leuprolide.]
[N06AX21, duloxetine, Leuprolide may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N04BX01, tolcapone, Leuprolide may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Leuprolide.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Letrozole.]
[S03AA01, neomycin, Leuprolide may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Leuprolide.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levosimendan.]
[B01AC17, tirofiban, Leuprolide may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Amphotericin B.]
[S01AA19, ampicillin, Leuprolide may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Leuprolide may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Leuprolide may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Leuprolide may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C01CE01, inamrinone, Leuprolide may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Niacin.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Leuprolide.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nimodipine.]
[C08CA07, nisoldipine, Leuprolide may decrease the excretion rate of Nisoldipine which could result in a higher serum level.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Leuprolide.]
[R07AX01, nitric oxide, Leuprolide may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Leuprolide may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Leuprolide may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Leuprolide may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Leuprolide may decrease the excretion rate of Nitroprusside which could result in a higher serum level.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Norfloxacin.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Leuprolide.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Leuprolide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ofloxacin.]
[N02AA02, opium, Leuprolide may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, Leuprolide may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[J01CF04, oxacillin, Leuprolide may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, Leuprolide may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Leuprolide.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Leuprolide.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Asenapine.]
[J04AB30, capreomycin, Leuprolide may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Papaverine.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Leuprolide.]
[G04BD11, fesoterodine, Leuprolide may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Leuprolide may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Penicillamine.]
[J01CE09, penicillin G procaine, Leuprolide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Leuprolide may decrease the excretion rate of Pentobarbital which could result in a higher serum level.]
[L01XX08, pentostatin, Leuprolide may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Leuprolide may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Leuprolide.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N06AF03, phenelzine, Leuprolide may decrease the excretion rate of Phenelzine which could result in a higher serum level.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Leuprolide.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Leuprolide.]
[V03AB36, phentolamine, Leuprolide may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N03AB02, phenytoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Phenytoin.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levofloxacin.]
[B02BA01, vitamin K1, Leuprolide may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Pimozide.]
[C07AA03, pindolol, Leuprolide may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Atorvastatin.]
[J01CA12, piperacillin, Leuprolide may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Saquinavir.]
[N06BX03, piracetam, Leuprolide may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Eprosartan.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Grepafloxacin.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Leuprolide.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Leuprolide.]
[B05XA01, potassium chloride, Leuprolide may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Leuprolide.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pitavastatin.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Leuprolide.]
[H02AB07, prednisone, Leuprolide may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Primaquine.]
[M04AB01, probenecid, Leuprolide may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Procarbazine.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Prochlorperazine.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Leuprolide.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Propafenone.]
[A03AB05, propantheline, Leuprolide may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Propofol.]
[C07AA05, propranolol, Leuprolide may decrease the excretion rate of Propranolol which could result in a higher serum level.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Propylthiouracil.]
[N02CC04, rizatriptan, Leuprolide may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, Leuprolide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Montelukast.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Leuprolide.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Leuprolide.]
[N07XX07, dalfampridine, Leuprolide may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Leuprolide may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Leuprolide may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Leuprolide.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quinine.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ranitidine.]
[C02AA02, reserpine, Leuprolide may decrease the excretion rate of Reserpine which could result in a higher serum level.]
[J05AP01, ribavirin, Leuprolide may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[N05CA06, secobarbital, Leuprolide may decrease the excretion rate of Secobarbital which could result in a higher serum level.]
[J01GB08, sisomicin, Leuprolide may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Leuprolide may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Leuprolide may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sotalol.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Alendronic acid.]
[C01DA14, isosorbide mononitrate, Leuprolide may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10AX03, azelaic acid, Leuprolide may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.]
